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Abstract
The tumor-associated carbohydrate Thomsen-Friedenreich antigen (TF-Ag; Galβ1-3GalNAcα-O-Ser/Thr) is overexpressed on the cell
surface of several types of tumor cells, contributing to cancer cell adhesion and metastasis to sites containing TF-Ag–binding lectins.
A highly specific immunoglobulin G3 monoclonal antibody (Ab) developed to TF-Ag (JAA-F11) impedes TF-Ag binding to vascular en-
dothelium, blocking a primary metastatic step and providing a survival advantage. In addition, in patients, even low levels of antibodies
to TF-Ag seem to improve prognosis; thus, it is expected that vaccines generating antibodies toward TF-Ag would be clinically valuable.
Unfortunately, vaccinations with protein conjugates of carbohydrate tumor-associated Ags have induced clinically inadequate immune
responses. However, immunization using peptides that mimic carbohydrate Ags such as Lewis has resulted in both Ab and T-cell
responses. Here, we tested the hypothesis that vaccinations with unique TF-Ag peptide mimics may generate immune responses
to TF-Ag epitopes on tumor cells, useful for active immunotherapy against relevant cancers. Peptide mimics of TF-Ag were selected
by phage display biopanning using JAA-F11 and rabbit anti–TF-Ag Ab and were analyzed in vitro to confirm TF-Ag peptide mimicry.
In vitro, TF-Ag peptide mimics bound to TF-Ag–specific peanut agglutinin and blocked TF-Ag–mediated rolling and stable adhesion
of cancer cells to vascular endothelium. In vivo, the immunization with TF-Ag–mimicking multiple antigenic peptides induced TF-
Ag–reactive Ab production. We propose that this novel active immunotherapy approach could decrease tumor burden in cancer pa-
tients by specifically targeting TF-Ag–positive cancer cells and blocking metastasis.
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Introduction
The tumor-associated carbohydrate antigen (Ag) Thomsen-Friedenreich
(TF-Ag) is present on tumor cells including those of breast, lung,
colon, bladder, and prostate [1–5]. TF-Ag, the core 1 disaccharide
Galβ1-3GalNAcα-O-Ser/Thr [1–3], remains cryptic on normal cell
membranes, covered by extended carbohydrate residues preventing ex-
posure of the epitope to the immune system [1–3], but becomes ex-
posed on cancer cell surfaces. An important role for TF-Ag has been
recognized in the process of cell adhesion and metastasis [1–7]. TF-Ag
binding moieties were found in sites of metastasis, offering an expla-
nation for the correlation between TF-Ag surface expression on cancer
cells and tumor aggressiveness and metastasis [4,6,7].
The human antibody (Ab) repertoire is known to contain low levels
of anti–TF-Ag antibodies, mainly of the immunoglobulin (Ig) M iso-
type [1,2,8–12]. Patients with higher levels of anti–TF-Ag Ab have a
better prognosis than patients with lower levels [1,2,8–13]. Thus, it
seems that naturally formed antibodies to TF-Ag may have a beneficial
effect even at relatively low levels. Additional indications that anti–TF-
Ag could be clinically important come from animal experiments on
spontaneous breast cancer metastasis, in which Ab to TF-Ag blocked
metastasis and improved survival [6]. Thus, the fact that some patients
generate Ab responses to TF-Ag that could be associated with better
prognosis inspires research into active immunization approaches to
supply anti–TF-Ag Ab to the patient.
Attempts to make Ab to TF-Ag in cancer patients began with a
TF-Ag vaccine composed of blood group type O-MN red blood
cell–derived glycoproteins, which resulted in improved breast cancer
patient survival, although only small amounts of IgM Ab were pro-
duced [14]. Studies with protein conjugates of Ags related to TF-Ag,
Tn, and sialyl Tn in colon cancer and sialyl Tn in breast cancer
patients [15–18] induced low level Ab responses, which were still
IgM-dominant, and some clinical responses were observed in these
patients. These results, although promising, indicated no memory
development, whereas one of the main reasons to use active immu-
nization rather than passive transfer is the anticipation of long-term
memory induction for protection from recurrences.
Peptide mimicry offers an alternative method for increasing car-
bohydrate Ag immunogenicity [19–21]. In cellular immunologic
responses to peptide mimics and subsequent cytotoxic responses, re-
cent results show that T cells primed by peptide mimics can sub-
sequently react with carbohydrate moieties, potentially inducing
cellular responses against carbohydrate epitope-bearing tumor cells
[22–27], indicating that vaccinations with peptide mimics may be
able to generate improved responses to carbohydrate epitopes on tu-
mor cells. Kieber-Emmons et al. [22] and Luo et al. [23] used mim-
icry of Lewis Ags by peptides to induce enhanced immune responses
and elicited T-cell–dependent versus T-cell–independent responses to
the Ag [22,23]. In addition, studies with peptide mimics of bacterial
carbohydrate Ags showed structural data supporting the ability of
peptides to mimic carbohydrate Ags, and these mimics were prepared
as conjugates for vaccine studies against the bacteria [28–30].
It seems that generation of an active immune response to TF-Ag
using peptide mimics holds the potential to be clinically useful in con-
junction with current therapies and, unlike passive transfer of Ab, to
prevent long-term recurrence by generating an effective immune mem-
ory in the patient. For these reasons, the focus of our study was on
developing and characterizing peptides that function as mimics of
the TF-Ag structure in vitro with the ultimate goal of using these pep-
tide mimics in vaccines for stimulating responses to TF-Ag.
Materials and Methods
Mimotope Selection, Phage Amplification, and Titering
Biopanning of phage expressing 12-mer peptides (New England Bio-
labs, Ipswitch,MA) [31,32] was performed on 96-well plates (Immulon;
Dynatech Laboratories, Chantilly, VA) coated with partially purified
JAA-F11 monoclonal Ab to Galβ1-3GalNAcα [3], for rounds 1 and
2. Round 3 of biopanning was performed on plates coated with partially
purified rabbit polyclonal Ab to Galβ1-3GalNAc-α, which was created
through immunization with a Galβ1-3GalNAcα-O-diazophenyl–BSA
conjugate, with the specificity described by Diakun et al. [33]. The
specificity of the JAA-F11 has been described in detail by Chaturvedi
et al. [34], and its production was described in Rittenhouse-Diakun
et al. [3]. Both antibodies require both the Gal and the GalNAc for
binding, a free 3-hydroxyl on the galactose was required by both for
binding, but neither Ab required a free 6-hydroxyl on the galactose
nor on theN -acetyl-galactosamine, and lastly, both Ab preparations pre-
ferred the Galβ1-3GalNAc-α linked to the Galβ1-3GalNAc-β–linked
structures. Nonspecific binding was blocked with 5 mg/ml BSA. Ini-
tially, 2 × 1012 phage per milliliter were added to the wells and incu-
bated for 45 minutes. Unbound phages were removed with 10 washes
of TBST (50 mM pH 7.5, Tris with Tween 20). Bound phages were
eluted with 10 mM TF-Ag disaccharide for 10 minutes with rocking
at room temperature (RT). Pooled selected phages were amplified
and titered according to the manufacturer’s protocols [31]. Final se-
lection of positive mimicking clones was performed using JAA-F11
Ab on transfer immunoblots from titer plates.
In Vitro Testing of Phage Mimicry
Immunoblot analysis. Ten microliters of phage dilutions was ap-
plied to a TBS-wetted nitrocellulose membrane using a slot blot appa-
ratus (BioRad, Hercules, CA) and blocked with 1% BSA-TBS. Primary
Ab or lectin (JAA-F11, mouse IgG3 isotype control, rabbit anti–TF-
Ag, or peanut agglutinin [PNA]; Vector Laboratories, Burlingame,
CA) was added and incubated for 1 to 2 hours. Immunoblot analysis
proceeded according to the manufacturer’s (Promega, Madison, WI)
protocol using an alkaline phosphatase secondary Ab followed by the
5-bromo-4-chloro-3-indolyl phosphate/nitro blue tetrazolium sub-
strate in the case of the antibodies and, in the case of PNA, by using
an Ab to PNA followed by an alkaline phosphatase–conjugated sec-
ondary Ab and substrate [35]. Analysis was performed using densi-
tometry (GS-700 Imaging Densitometer; Biorad).
Inhibition ELISA. ELISA microtiter plates (Immulon) were coated
with 5 μg/ml TF-Ag–BSA conjugate in sodium bicarbonate buffer for
3 hours at 37°C. Plates were washed three times, and an inhibiting
agent (selected phage) was mixed with equal volumes of primary Ab
and incubated for 1 to 2 hours at 37°C. The mixture was added to the
plate and incubated at 37°C for 1 to 2 hours. After washing, anti-
mouse IgG alkaline phosphatase conjugate (Sigma, St. Louis, MO)
was added and incubated at RT. After washing, para-nitrophenyl phos-
phate substrate (Sigma) was added. After incubation, the plate was
read at 405 nm. Inhibition ELISAs were performed with JAA-F11,
rabbit Ab to TF-Ag, and PNA mixed with phage.
Phage DNA Purification and Sequencing
DNA was purified from individual phage clones by an adaptation
of standard protocol for DNA purification from M13 phage [31,36].
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The 36-bp insert of interest was identified and translated to deter-
mine the unique 12–amino acid sequence of the selected phage. Pep-
tides were produced containing the 12 amino acids plus the next
three residues at the C-terminus in the phage sequence (GGG),
and a cysteine or serine residue was added for conjugation purposes.
Solid-Phase Peptide Synthesis and Analysis
Solid-phase peptide synthesis (SPPS) was used to produce 16–amino
acid peptides with Fmoc-based chemistry using standard protocols
[37,38]. The peptides were purified using reverse-phase high-performance
liquid chromatography (HPLC) on aVydacC18 column (GraceDavison,
Deerfield, IL). The purity of the peptides was confirmed by analyti-
cal HPLC, and the identity was confirmed by matrix-assisted laser
desorption/ionization–time of flight. Additional peptides were pur-
chased from Sigma-Genosys (TheWoodlands, TX) and Bio-Synthesis,
Inc (Lewisville, TX). Multiple antigenic peptides (MAPs) were pro-
duced by SPPS using Fmoc chemistry onto a branched lysine core re-
sulting in eight 15-mer peptides presented on one structure (Figure 1;
Bio-Synthesis, Inc). Previous studies have successfully produced TF-
Ag conjugated to the MAP core [39,40]. Inhibition ELISAs was used
to test ability of single peptide mimics to inhibit binding of Ab to
TF-Ag as previously mentioned. Six different MAPs were produced
as described, five containing selected TF-Ag mimicking sequences
and one containing a negative control, using an ovalbumin (Ova) se-
quence (Table 1). Peptides were stored at −20°C under nitrogen in
lyophilized form. Corresponding linear peptides were used in ELISAs.
Surface Plasmon Resonance Using Biacore
Binding kinetics were determined by surface plasmon resonance
(SPR) using a BIACORE X biosensor system (Biacore, Piscataway, NJ)
and defined experimental design [41,42]. JAA-F11 Ab to TF-Ag was
immobilized on CM5 dextran sensor chips using amine-coupling chem-
istry reagents (Biacore). Approximately 10,000 resonance units (RUs)
of JAA-F11 was immobilized, providing an active surface of 3000 to
4000 RU corresponding to 3000 to 4000 pg/mm2. All measurements
were carried out in HBS-EP buffer (0.01 M HEPES pH 7.4, 0.15 M
NaCl, 3 mM EDTA, 0.005% surfactant P20; Biacore). Surface inter-
actions were performed at 25°C at flow rates of 5 or 10 μl/min using a
reference cell versus an experimental cell. RU values for Ag binding
ranged from 5 to 250. Surface regeneration was performed using
10 mM HCl or 10 mM glycine pH 2.0 at 50 μl/min. Kinetic param-
eters for the binding of JAA-F11 to peptide D2 were determined using
the BIAevaluation programs.
In Vitro Adhesion Assays
Cell lines and cultures. The MDA-MB-435 human metastatic
cancer cell line was kindly provided by Dr. J.E. Price (MD Anderson
Cancer Center). MDA-MB-435 cells were maintained on plastic in
5% CO2/95% air using the RPMI-1640 medium supplemented
with L-glutamine, 10% fetal bovine serum, sodium pyruvate, and
nonessential amino acids. The HBME-1 human bone marrow endo-
thelial cell line was kindly provided by Dr. K.J. Pienta (University of
Michigan) and grown as previously described [43].
In vitro parallel flow chamber assay. The adhesion of MDA-MB-
435 cells to HBME-1 monolayers was studied in vitro with and with-
out inhibitory molecules in a parallel plate laminar flow chamber as
described previously [44]. Data are presented as the means ± SD of
two independent experiments.
Prediction of Major Histocompatibility Complex Binding
SYFPEITHI [45], BIMAS [46], and RANKPEP [47] databases were
used for major histocompatibility complex (MHC) binding algorithms.
Sequence Homology
The Basic Local Alignment Search Tool (BLAST) database was
used [48] for sequence comparison to known proteins. The amino
acid sequences were entered into the protein short, nearly exact se-
quence comparison database using limitation to Homo sapiens and
Mus muscularus organism sequences.
Immunization Protocols
A vaccination protocol involving 200 Balb/c mice divided evenly
into eight groups was used (Table 1). All blood draws were obtained
by retro-orbital bleed, under 3% isoflurane anesthesia. To prepare
each vaccination mixture, 3 mg of MAP was dissolved in 1.5 ml
of sterile-filtered PBS (2 mg/ml) and, 1.2 ml of Alum adjuvant (alu-
minum hydroxide at 40 mg/ml; Pierce) was added dropwise. After
mixing for 30 minutes, 0.3 ml of inactivated Bordetella pertussis
suspension at 200 × 109 organisms per milliliter (Wako Chemicals,
Richmond, VA) was added to the tube and mixed to homogeneity.
One hundred microliters was injected into each mouse, divided into
four sites at the back. Thus, each mouse received 100 μg of MAP plus
1.6 mg of Alum and 2 × 109 B. pertussis organisms as adjuvant per
Figure 1. The structure of the D2 MAPs that were produced by
SPPS using Fmoc chemistry onto a branched lysine core resulting
in eight 15-mer peptides presented on one structure. Other pep-
tide MAPs were prepared similarly.
Table 1. Sequence of MAP Peptides and Immunization Groups.









*Sequence B1 was obtained three times; clones C2 and D3 also contained this sequence (not listed).
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immunization [49,50]. A primary vaccination and three booster im-
munizations at 2-week intervals were given to each mouse. After the
prebleed, four additional blood draws were obtained, 2 weeks after
each immunization (Table 1). All animal experimentation was done
using approved institutional protocols, in a facility approved by the As-
sociation for Assessment and Accreditation of Laboratory Animal Care.
Serum Analysis
Indirect ELISAs were performed on Immulon microtiter plates:
for the first group of mice, sera from all five blood draws from each
of the 200 mice were tested for IgG and IgM Abs in triplicate on
both TF-Ag–BSA–coated plates (1:50), on linear peptide–coated
plates (1:200, 1:400, and 1:800) corresponding to the MAP used
for immunization and on Ova linear peptide–coated plates for IgG
and IgM Abs (1:200, 1:400, and 1:800). Sera dilutions were incu-
bated for 2 hours at 37°C; the plates were washed three times with
1× TBS-Brij, and anti–mouse IgG alkaline phosphatase conjugate
(1:1000; Sigma) was added and incubated at RT for 1 hour. The
plates were washed three times as previously, and p-nitrophenyl phos-
phate substrate (Sigma) was added for 1 hour, after which the plates
were read at 405 nm on a spectrophotometer. The plates were washed
three times as previously mentioned, and anti–mouse IgM–horseradish
peroxidase conjugate (1:4000; Sigma) was added to each plate and
incubated for 1 hour at RT. The plates were washed three times and
O-phenylenediamine substrate (Sigma) was added for 1 hour and read
at 450 nm.
Statistical Analyses
The averages of the triplicates were determined for each mouse in
each group and used as the unit of analysis. Groups were then com-
pared by Student’s t tests. This allowed for comparison of the Ab
levels from preimmunization to weeks 6 and 8 within each group,
as well as the levels between groups. To simplify the analysis, the
higher value of week 6 or week 8 was used as the postimmunization
level comparisons. In the analysis of the serum Ab response by en-
zyme immunoassays, to describe the observed variability in the data
and test for difference between groups, a mixed linear model was fit
to each end point, optical density (OD) IgG, and OD IgM. Once
the model was fit, specific linear contrasts based on the model pa-
rameters were constructed and used to test for mean differences be-
tween the two control groups (Ova and PBS) and each of the six
experimental groups (B1, B3, C1, D1, D2, and Mix) at both 6
and 8 weeks. To control for multiple testing, Bonferroni-adjusted
P values were computed for all 24 hypothesis tests, thereby bounding
the experiment-wise error rate at 0.05 per end point. Standard diag-
nostic tools were used to assess model fit. Also computed for each
end point was the response rate by group based on the absolute
change for a variety of cut points. Microsoft Excel (Microsoft, Red-
mond, WA), Minitab Release 14 (Minitab, Inc., State College, PA),
and SAS version 9.0 statistical software (SAS, Cary, NC) were used
for all analyses. Standard diagnostic plots for normal-based models
were used in all analyses, and model fit was deemed adequate.
Results
Biopanning, Mimic Isolation, and Selection
Biopanning with mouse monoclonal Ab and rabbit Ab eluted with
TF-Ag decreased the likelihood of nonspecific binding to Ab. To carry
out successful biopanning, a titer of 1 to 2 × 109 plaque-forming units
(PFUs)/100 μl or greater was required with high stringency con-
ditions. The percent recovery of binding phage increased with each
round of biopanning. Final phage amplification and selection were
performed with immunoprobing of titered phage followed by posi-
tive phage amplifications.
Amplification of isolated phage was needed to obtain a sufficient
amount of phage for subsequent experiments. The phage pellet was
titered to determine the number of PFUs. Successful phage titers,
appearing as plates with well-separated colonies, were obtained using
dilutions from 1 × 105 to 1 × 1011. Typical titers were in the range of
3 to 5 × 109 PFU/ml.
To isolate phage containing TF-Ag mimics, a transfer of phage to
nitrocellulose from Luria Bertani plates with well-separated colonies
was performed, and the membrane was incubated with JAA-F11 Ab
to TF-Ag, followed by anti–mouse enzyme-conjugated Ab and cor-
responding substrate for color development. Specific colonies cor-
responding to phage mimics appeared purple, whereas phage that
did not mimic, as well as wild-type phage, appeared white. Positive
colonies were plucked from the titer plates and amplified again to gen-
erate distinct positive phage clones that mimic TF-Ag.
Immunoblot analysis. To analyze phage pools selected by biopan-
ning, four immunoblots were performed. The pooled phage mixture
blotted at different concentrations on nitrocellulose was probed with
JAA-F11 Ab (Figure 2A), rabbit polyclonal anti–TF-Ab (Figure 2B),
or PNA, a TF-Ag–binding lectin (Figure 2C ). In each case, the im-
munoblot demonstrated specific binding to the positive phage pool
and not to the negative phage pool. Next, the phage pool was probed
with an isotype control IgG3 Ab, 4A11, specific for pneumococcal
saccharide, compared with JAA-F11 binding (Figure 2D). These ex-
periments demonstrated that pooled phage contained specific phage
isolates able to mimic TF-Ag and bind mouse monoclonal anti–TF-Ag
JAA-F11 Ab, rabbit polyclonal anti–TF-Ag Ab, and TF-Ag–specific
PNA but not a control Ab.
Individual phage clones were selected using transfer immunoblots,
in which positively reacting phage were plucked and amplified to
produce individual positive phage clones. Figure 2 shows the blot
quantitation of five individual phage clones and their reactivity with
JAA-F11 Ab (Figure 2E ), rabbit Ab to TF-Ag (Figure 2F ), and PNA
lectin (Figure 2G ). Phage clones were tested at the following: B1 and
B3—5 × 109 PFU/ml, C1 and D2—4 × 109 PFU/ml, D1—3 ×
109 PFU/ml, E—6 × 1013 PFU/ml. A representative of multiple
experiments is shown. These experiments show that selected individ-
ual phage clones are creating a peptide conformation similar enough
to TF-Ag to bind TF-Ag–specific Abs and lectin, supporting the
theory that they mimic TF-Ag.
Inhibition ELISA. To further show that selected phage clones do
mimic TF-Ag, inhibition ELISA was performed using JAA-F11 Ab.
Phage inhibited JAA-F11 binding to TF-Ag–coated plates by varying
amounts (Table 2). D2 phage showed the highest amount of inhibi-
tion (49%). These experiments indicated that three of the five phage
clones at 5 μg/ml in solution bound JAA-F11 well enough to prevent
binding of JAA-F11 to TF-Ag, the original target carbohydrate Ag. A
representative of three experiments is shown.
Phage Sequencing
To identify the peptides that were able to mimic TF-Ag in immu-
noblot analysis and inhibition ELISA experiments, the selected phage
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Figure 2. Immunoblot quantitation of bound pooled phage (A–D) and bound individual phage clones (E–G). (A–D) Pooled positive and
negative phage (at 2.8 × 1010 and 2.2 × 1010 PFU/ml, respectively) were diluted 1:1, 1:2, 1:4, and 1:8. (E–G) Phage clones (B1, D2, B3,
C1, D1, E) were diluted 1:1, 1:2, and 1:4 for probing with Ab. (A and E) JAA-F11 monoclonal Ab (20 μg/ml) reactivity. (B and F) Rabbit
polyclonal sera to TF-Ag (1:50). (C and G) PNA lectin (200 μg/ml) reactivity. (D) JAA-F11 and an isotype matched control (IgG3). Blots were
quantitated by densitometry and reflected density of the spots represented on the y-axes. TF-Ag–BSA was used as a positive control;
TBS-BSA was used as the negative control.
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were sequenced. Three phage clones returned the same sequence (B1,
C2, and D3), providing evidence of a good mimicking sequence, and
additional four different sequences were obtained. These five se-
quences are listed in Table 2 as the 12-mer sequences followed by
the next four residues present in the phage (GGGS). Of the five
different sequences that were returned, the D2 phage reacted best
in the immunoblots and inhibition ELISAs and was initially chosen
as the focus of further studies.
BLAST Search
Using the National Center for Biotechnology Information BLAST
database of known proteins, analysis was performed with the 15 amino
acids that were input for the mimicking sequences (of which only
the first 12 are considered part of the mimicking sequence), only par-
tial matches were generated, with gaps in the compared sequences,
which would not be likely to cross-react because the residues are not
sequential. No 15/15 matches were generated for any of the five pep-
tide mimic sequences. No significant findings were identified that
would indicate similarity to other known proteins that would cause
autoimmunity or tolerance in vivo.
In Vitro Evidence of TF-Ag Mimicry by Selected Phage
Peptide synthesis. Short single peptides corresponding to the 12–
amino acid phage insert plus the 4–amino acid spacer were produced
as 16-mer peptides. Cysteine was inserted in place of serine for ease of
conjugation to carrier proteins. Eight peptides of the same sequences
were linked to a 7-branched lysine core to produce MAP peptides (Fig-
ure 1) based on phage sequences that were found to act as mimics and
a negative control MAP from Ova (SIINFEKLGAGAGGG).
In Vitro Evidence of TF-Ag Mimicry by Synthetic Peptides
Inhibition ELISAs. The purified D2 peptides were used in inhi-
bition ELISA experiments as described in the previous sections. In-
hibition, indicating specific binding, was seen with JAA-F11 Ab (up
to 43%), rabbit Ab to TF-Ag (10%), and PNA (18%). These experi-
ments show that D2 peptide is able to mimic TF-Ag by partially in-
hibiting the binding of Abs and a lectin known to bind TF-Ag with
high specificity. When the B3 peptide was synthesized and tested
with JAA-F11, it was also able to partially inhibit binding (50%).
The levels of inhibition of rabbit Ab and PNA by D2 were not as
high, likely because of the difference in affinity of the Ab for the uni-
valent peptide versus the multivalent phage conjugate and multivalent
TF-Ag conjugate, as the TF-Ag conjugate inhibited JAA-F11 Ab by
99% but only inhibited rabbit Ab by 62% and PNA by 14%.
Immunoblots. Immunoblots were performed as previously men-
tioned on peptides and were found to also bind JAA-F11 (data
not shown).
Surface Plasmon Resonance
To determine the affinity of JAA-F11 Ab for a peptide mimic, SPR
was performed using the Biacore system. An affinity, the KD (M) for
JAA-F11 binding to the single D2 peptide, was determined to be
5.73 × 10−4 M, in the submillimolar range of binding (Figure 3A).
In Vitro Adhesion
An in vitro adhesion system was used to demonstrate that peptide
mimics, similar to TF-Ag [4] and Ab to TF-Ag [6], could block the
adhesion of metastatic cancer cells to vascular endothelial cells, as a
model of the in vivo mechanism of action. The D2 peptide was able
to significantly inhibit rolling adhesion by approximately 43% and
stable adhesion by approximately 71%, indicating that the binding
of D2 peptide to the natural TF-Ag ligands on the vascular endothe-
lium prevented TF-Ag expressed on the tumor cells from binding
(Figure 3B). Importantly, when JAA-F11 Ab was used in this model
system, it also significantly blocked rolling and stable adhesion of
cancer cells to the endothelial cells [6]. In vivo, JAA-F11 significantly
reduced metastasis of breast tumor cells, and the adhesion system
provides a mechanism of action for JAA-F11 blocking the adhesion
of cancer cells to metastatic sites [6]. Additional peptide mimics are
currently being tested in this functional model system of adhesion.
MHC Prediction
Using MHC binding prediction databases, it was determined that
the isolated peptide sequences are likely to be bound and presented
by many MHC molecules, in both mouse and human and by both
class I and class II molecules (data not shown). This indicates that
peptides used in immunizations have the ability to be presented by
MHC molecules to T cells for potential reactivity. Of the mice used
in this study, the Balb/c strain harbors H2-d MHC molecules and the
C3H strain harbors H2-k MHC. With regard to humans, the MHC
molecules able to bind these peptides in the search are common hu-
man leukocyte antigen A and B (HLA-A and HLA-B) classes in the
population, giving relevance to this search [51]. The MHC predic-
tions are based on known binding algorithms and thus accurately re-
flect the ability of the peptide to bind and be presented in vivo in a
large portion of the population, with additional in vivo support.
For relevance, the maximal scores given for these peptide mimics
were compared with the scores found for another published peptide
mimic of a carbohydrate tumor Ag, Lewis Y. This peptide mimic
(GGIYWRYDIYWRYDIYWRYD) used in immunizations was shown
to elicit IgM and IgG antibodies and to induce carbohydrate reactive
T cells [25]. Therefore, the maximal binding scores to class I mole-
cules of this peptide epitope were compared, and all MHC molecules
listed are predicted to bind at least one peptide mimic. This informa-
tion predicts that the peptides, when injected in mice, can be pre-
sented by at least several of the haplotypes present.
MAPs and Linear Peptides
After confirming the correct sequences of the MAPs and linear
peptides by HPLC and mass spectrometry analyses, immunoblots
Table 2. Peptide Reactivity and Percent Inhibition of JAA-F11 Binding.
Name Sequence of Selected Phage % Inhibition Reactivity with
JAA-F11 Rabbit Ab PNA
D2 HIH GWK SPL SSL GGG S/C 49% ++ ++ ++
*B1 HHS HKT NLA TTP GGG S/C 21% ++ ++ ++
B3 GHP HYI THK PNR GGG S/C 21% + +/− ++
C1 YPS LPV YHS LRS GGG S/C 0 +/− +/− +
D1 MHK PWS GHM QVP GGG S/C 0 +/− ++ −
E Negative phage pool 0 − NT NT
++ indicates strong binding; +, moderate binding; +/−, weak binding; −, no binding; NT, not tested.
*Relative reactivity of phage clones in immunoblots with JAA-F11, Rabbit Ab to TF-Ag, and PNA,
a TF-Ag binding lectin, with phage are listed in order of reactivity with JAA-F11 in immunoblot.
Sequence B1 was obtained three times; C2 and D3 also showed this sequence (not shown).
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were performed to determine the reactivity with JAA-F11 Ab. JAA-
F11 binding was seen to B1, D2, and C1 MAPs, whereas a lack of
binding was seen to B3, D1, and Ova MAPs (data not shown). All
five linear peptide mimicking sequences were found to bind to JAA-
F11 under optimized experimental conditions (data not shown) and
were used for the subsequent sera analyses.
Immunization
Serum analysis. Linear peptides corresponding to the same se-
quences used in the MAPs were used. The preimmunization (Pre),
week 6, and week 8 sera were tested in triplicate at 1:200, 1:400, and
1:800 on linear peptide–coated plates (corresponding to the MAP
used for immunization) as well as Ova linear peptide–coated plates
for IgG and IgM Abs. This allowed for the determination of the
levels of Ab made to the immunized peptide to ensure that the im-
munizations were successful in eliciting a robust immune response.
Good immune responses toward the peptides were seen. This analy-
sis also allowed for the detection of any Ab that reacted with the nega-
tive Ova peptide, which would indicate nonspecific Ab to any MAPs
or to the lysine core, rather than specific Ab to the peptide sequences.
No cross-reactive Ab between the peptides was seen (data not shown).
The Pre, week 6, and week 8 sera were tested at 1:50 in triplicate on
TF-Ag–BSA–coated plates for IgG and IgM Abs. These assays yielded
measurable levels of specific Ab without high levels of background
binding in the sera. To determine whether an early immune response
occurred, which was missed, 33 additional mice were vaccinated, and
their sera were obtained on day 7. The sera from the 7-day study were
tested in triplicate at 1:50 on TF-Ag– and linear peptide–coated plates
for IgG and IgM Abs. At 7 days, the levels of IgM Ab might be ex-
pected to be higher than at day 14. However, little Ab response, IgG,
or IgM was seen at this time point (data not shown).
Statistical analyses. The Abs produced to immunized peptide and
the control Ova peptide were compared using the same dilutions as
previously mentioned to compare the responses to the different pep-
tides. Screening of sera from six mice per group was analyzed, show-
ing that D2, B3, C1, and Ova peptides caused production of greater
Figure 3. (A) Biacore (SPR) analysis of JAA-F11 binding to D2 peptide. Table shows binding kinetics for the binding of JAA-F11 to D2
peptide (using BiaEval software), and figure displays the range of D2 peptide concentrations binding to JAA-F11. JAA-F11 Ab coupled
to a CM5 sensorchip was used to detect the binding of D2 to the Ab. The sensorgram graph is representative of several binding experi-
ments, showing the dose–response of peptide binding to JAA-F11 versus time. (B) Two peptide mimics blocking rolling and stable adhe-
sion of MD-MBA-235 human breast cancer cells to HBME-1 human bone marrow endothelial cells in vitro. Adhesion of MDA-MB-435 cells
to HBME-1 cells using a parallel plate laminar flow chamber was assessed. The percent rolling MDA-MB-435 cells and number of stably
adherent cells per field determined during 1- and 5-minute periods, respectively, in at least three different observation fields for each ex-
perimental setting. Control indicates no peptide; Negative, nonrelated peptide. Data are presented as mean ± SEM of two independent
experiments. *D2 significant inhibition, corresponding to 43% inhibition of rolling and 71% inhibition of stable adhesion.
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amounts of Ab; D1, B1, and the mixture of peptides caused moder-
ate production of Ab; and PBS alone did not result in Ab production.
The anti–TF-Ag response was tested with sera at a 1:50 dilution.
Statistically significant increases from preimmunization to postim-
munization were seen within each group (Figure 4, A–D) showing
that the immunization protocol was effective in eliciting an immune
response by itself because increases were seen in the negative groups
as well. Comparisons between groups were also made (Figure 4, E–
H ). Both IgG and IgM productions were tested. These dot plots al-
low for the distribution of the responses in each group to be seen as
well as the mean of each group. Table 3 summarizes this information.
Additional line graphs visualize the response trends over the time
points tested in each group. To further and more accurately analyze
the Ab response, a more complex statistical analysis was performed,
as explained previously. This model allowed for the consideration of
different baseline levels of Ab and statistically compared the differ-
ences among groups using more stringent constraints. Therefore,
fewer groups showed a significant response over the controls groups
by this analysis. For IgG Ab to TF-Ag, statistically significant results
were found between B1 and each of the control groups at both the 6-
and 8-week time points (P < .0001; Figure 5A). All other compari-
sons with the control groups were found to be nonsignificant. For
IgM Ab to TF-Ag, statistically significant results were found between
C1 and Ova (P = .0312) and between C1 and PBS (P = .0012) at the
6-week time point. At the 8-week time point, significant differences
were found between C1 and Ova (P = .0007), C1 and PBS (P <
.0001), and B1 and PBS (P = .0016; Figure 5B). All other compar-
isons with the control groups were found to be nonsignificant.
Whereas fewer groups were found to be significant, the stringency
of this model suggests that the groups that are significant are repre-
senting a true and valid anti–TF-Ag response to the peptide mimics.
The previously mentioned analyses at 1:50 consider each group as
a whole by averaging the group responses and then performing anal-
yses. However, individual mouse responses can vary, and therefore,
examining the responses of individual mice was performed. The most
accurate method to analyze each mouse singly was to quantitate the
absolute change in OD, correcting for the differences in baseline Ab
levels among mice. The absolute changes in OD for IgG and IgM
Abs for each mouse were determined and represented as individ-
ual points on a dot plot (Figure 4, A–H ). The percentage of mice
in each group, which changed by a given amount, was counted. At
the 0.2 OD change cut point, definite differences between groups are
seen. For IgG Ab to TF-Ag, B1, C1, and D1 groups all have percent-
ages of mice that are considerably higher than those in control Ova
and PBS groups. B3, D2, and Mix groups, although not as high as
B1, C1, and D1 groups, still have double the number of mice that
responded with greater than 0.2 OD change over the negative groups
(Figure 6A). For IgM Ab to TF-Ag, B1, C1, and D1 groups all have
Figure 4. (A–H) Dot plots of all mice at 1:50, IgG and IgM to TF-Ag, at the same scale. Significance marked: *P, difference from Pre to
Post, mean = ⊗. (A an B) IgG to TF-Ag, all mice. (C and D) IgM to TF-Ag, all mice. (E) Pre and (F) Post bleed IgG to TF-Ag levels for all
groups, respectively, to visualize the difference in the baseline (E) and response (F) levels between groups. (G) Pre and (H) Post bleed
IgM to TF-Ag levels for all groups, respectively, to visualize the difference in the baseline (G) and response (H) levels between groups.
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Figure 4. (continued)
Table 3. Immunized Sera Tested for Production of Reactive Ab to TF-Ag (1:50 Dilution).
Group: Pre vs Post Significance: IgG to TF-Ag (P < .05) Fold Increase in OD from Pre to Post Significance: IgM to TF-Ag (P < .05) Fold Increase in OD from Pre to Post
D2 1.48 × 10−6 4-fold 4.02 × 10−5 2.2-fold
B3 7.03 × 10−6 4.2-fold 8.98 × 10−5 2.2-fold
C1 7.78 × 10−7 6.7-fold 2.44 × 10−6 3.2-fold
B1 1.05 × 10−4 7.5-fold 1.11 × 10−5 2.7-fold
D1 6.67 × 10−11 2.7-fold 7.74 × 10−4 2.3-fold
Ova 9.47 × 10−8 2.7-fold .0155 1.67-fold
Mix 3.56 × 10−10 2-fold .048 1.3-fold
PBS 1.86 × 10−7 1.9-fold .68 0
Groups: (Post vs Post) Significance: IgG to TF-Ag (P < .05) Fold Increase from Post to Post Significance: IgM to TF-Ag (P < .05) Fold Increase in OD from Pre to Post
D2 vs Ova NS NS NS NS
D2 vs PBS NS NS NS NS
B3 vs Ova NS NS NS NS
B3 vs PBS NS NS NS NS
C1 vs Ova .178 1.24-fold .007 1.64-fold
C1 vs PBS .093 1.35-fold 5.7 × 10−5 2.16-fold
B1 vs Ova .013 2-fold .18 1.3-fold
B1 vs PBS .005 2.18-fold .002 1.7-fold
D1 vs Ova .42 1.14-fold .404 1.2-fold
D1 vs PBS .04 1.24-fold .036 1.6-fold
Mix vs Ova .29 1.15-fold .87 1.02-fold
Mix vs PBS .057 1.26-fold .049 1.35-fold
Ova vs PBS .45 .18
Using Student’s t test (paired) to determine significance between Pre and Post (using the highest value of bleed 3 or 4) and Post to Post in each group, and the averages of each group used. No statistical
calculations were used to compare fold differences in this case. Insignificant values for D2 and B3 partially reflect the lower baseline level in these groups compared with the controls.
NS indicates not significant.
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Figure 5. IgG (A) and IgM (B) line graphs of the average Ab level to TF-Ag tested at 1:50 of all mice in each group during three time
points. Statistically significant results were found between B1 and each of the control groups (Ova and PBS) at both time points (P <
.0001). All other comparisons with the control groups were found to be nonsignificant. At time point 6, statistical significant results were
found between C1 and Ova (P = .0312) and between C1 and PBS (P = .0012). At time point 8, significant differences were found
between C1 and Ova (P = .0007), between C1 and PBS (P < .0001), and between B1 and PBS (P = .0016). All other comparisons with
the control groups were found to be nonsignificant.
Figure 6. (A) Absolute changes in OD for IgG Ab to TF-Ag in each mouse per group, mean =⊗. (B) Absolute changes in OD for IgM Ab to
TF-Ag in each mouse per group, mean = ⊗.
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percentages of mice that are considerably higher than the control Ova
and PBS groups. B3, D2, and Mix groups have comparable numbers
of mice that responded with greater than 0.2 OD change compared
with the negative groups (Figure 6B). Considering the fact that B1,
C1, and D1 groups have appreciably more mice with 0.2 OD change
in Ab levels and the cut points used in this analysis, these data suggest
that these groups contain mice that exhibited significant responses,
representing true and valid responses to peptide mimics.
Discussion
In this study, we have used TF-Ag, which is a pan-carcinoma tumor
cell surface carbohydrate Ag, as the target for an immune response.
By developing peptide mimics of the carbohydrate structure for use
in vaccines, it is anticipated that we can begin a process that will
ultimately result in a clinically relevant immune response to TF-Ag
epitope-expressing tumor cells.
Through several methods of in vitro characterization of selected pep-
tides, it was shown that mimicry of TF-Ag occurs. Abs to TF-Ag, both
mouse monoclonal and rabbit polyclonal, as well as PNA lectin known
to bind TF-Ag, bound to the peptide mimics as well. The peptides
partially inhibited the binding of TF-Ag Abs to TF-Ag disaccharide-
protein conjugates by ELISA. The D2 peptide significantly inhibited
stable and rolling adhesion of TF-Ag epitope-expressing tumor cells to
human endothelial cells. These data may offer a potential mechanism
for Ab generated toward TF-Ag in vivo in blocking cell-cell adhesion
and thus prevent metastasis to distant sites.
The peptide mimics may further function to stimulate an immune
reaction that responds to TF-Ag epitope-expressing tumor cells.
BLAST analysis showed that an immune response to these peptides
should not cause an autoimmune reaction, and MHC binding pre-
diction analysis showed that these peptides are likely to be presented.
To achieve successful peptide mimic immunizations, Ab that binds
TF-Ag should be produced. Four different analyses were used to en-
sure comprehensive characterization of the Ab responses, as seen in
some peptide mimic-immunized groups, albeit low levels. Statistically
significant increases in Ab levels were seen from preimmunization to
postimmunization sera. This is an important result, showing that it
Figure 6. (continued)
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is possible to create Ab to TF-Ag peptide mimics, which reacts with
TF-Ag itself. Each peptide elicited varying levels of response, signify-
ing that not all peptides are equal mimics in vivo. This was not un-
expected, given that the peptides do differ greatly in sequence and
therefore chemical character. It is also not surprising that the peptides
behave differently in in vitro assays than in the in vivo environment.
Because of these differences, it was important to immunize with all of
the potential peptide mimics regardless of their in vitro activity. B1,
which did not react highly with JAA-F11 Ab in vitro, displayed the
highest immunogenic response in vivo. Peptide immunizations pro-
duced moderate to high levels of Ab reactive with the immunized pep-
tide itself, showing that the peptide immunogenicity was adequate,
and any lack of TF-Ag Ab was not due to suboptimal immunization
conditions. There was little to no cross-reactivity with the negative Ova
peptide, showing that Ab responses were peptide sequence-specific.
Little to no Ab was seen at 1-, 2-, and 4-week time points, but at
the 6- and 8-week time points, significant Ab levels were generated.
The most promising peptide before the in vivo immunizations was
D2. The lack of success of this peptide MAP led to subsequent stud-
ies that showed that the D2 peptide is relatively unstable, thus the
peptide could have been modified or broken down during the course
of the immunization protocol and not able to sufficiently act as a
mimic in vivo. This eventual loss of reactivity seen after long-term
storage was due to the apparent oxidative modifications to the peptide.
This corresponded to a change in the molecular weights of the pep-
tide as demonstrated by matrix-assisted laser desorption/ionization–
time of flight (data not shown). One modification was an increase
of 32 in the molecular weight, which could be attributed to addi-
tion of two oxygen atoms to the peptide by oxidative reactions.
Subsequent electrospray ionization–mass spectrometry analysis sug-
gested that either the tryptophan or proline residue of the D2 pep-
tide was modified (data not shown), suggesting that either of these
residues is critical for binding.
These results, showing Ab reactive to TF-Ag after peptide immu-
nizations, is encouraging for the use of peptide mimics. The fact that
IgG Abs were generated is a positive sign of T-cell involvement, and
T-cell immunity relative to carbohydrates has attracted great atten-
tion in recent years [52]. If the response to TF-Ag peptide mimics
can be increased using better peptide mimics or other improved tech-
niques to generate higher levels of TF-Ag–reactive Ab with T-cell
involvement, this research would have greater applicability. The cre-
ation of an immune response to TF-Ag through peptide mimics can
be used to decrease the tumor burden of cancer patients, concurrent
with leading treatments. The added benefits of this technique in-
clude the ability to differentially target TF-Ag–positive tumor cells
and block metastatic adhesion through the development of Ab to
the specific carbohydrate Ag.
The current data illuminating the development and characteriza-
tion of peptide mimics of TF-Ag provide in vitro support for the
functionality of these mimics and continued study of mimics for vac-
cine development directed at TF-Ag epitope-expressing tumor cells.
On further studies to improve the peptides, including crystallization
and modeling analysis, vaccination schemes using peptide mimics have
the ability to be applied for the prevention of recurrence of TF-Ag
epitope-expressing adenocarcinomas by generating an immune re-
sponse that targets and blocks TF-Ag. The widespread applicability
of the use of peptide mimics of TF-Ag makes it a significant area
of research for further exploration. Owing to the importance of
breaking tolerance to TF-Ag, a second vaccine approach will be at-
tempted, which will use constructs containing TF-Ag mimicking pep-
tides linked to the mucin-1 peptide and additionally linked to one or
more immune-enhancing agents including C3d, the T-cell–stimulating
peptides, zwitterionic constructs, and Toll-like receptor agonists. The
peptides will facilitate effective T helper cell response, reacting with
multiple HLA molecules. C3d will facilitate activation of B cells
without T-cell help by targeting CD21, the C3d receptor, on splenic
marginal zone B cells, and follicular dendritic cells [53]. Zwitterions
will generate Toll-like receptor agonists, and these will facilitate up-
take and activation of Ag-presenting cells [54,55]. These additional
vaccine strategies could improve the immunogenicity of the peptide
mimics toward the TF-Ag tumor epitope.
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